File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Asbestos-related lung cancer: Clinical characteristics and survival outcomes in an Australian cohort seeking workers compensation

TitleAsbestos-related lung cancer: Clinical characteristics and survival outcomes in an Australian cohort seeking workers compensation
Authors
Keywordsasbestos
cancer risk factors
carcinogenesis
clinical epidemiology
lung cancer
Issue Date2022
Citation
Asia-Pacific Journal of Clinical Oncology, 2022, v. 18, n. 5, p. e448-e455 How to Cite?
AbstractBackground and objectives: Due to difficulties in identifying sufficient-sized cohorts there remains uncertainty about prognostic and clinical differences that may be unique to asbestos-related lung cancer (ARLC). In this study, we use the Helsinki Criteria to define a group of ex-workers with lung cancer attributable to asbestos exposure and investigate differences that may exist. Methods: A total of 529 patients seeking workers’ compensation for their lung cancer were assigned to either ARLC or the non-ARLC based on parameters defined in the Helsinki Criteria. Clinical and survival details were collected and analyzed. Results: In our study population, ARLC patients were on average older (72.1 ± 7.8) than non-ARLC patients (66.5 ± 10.2, P < 0.001) and were more likely to be diagnosed as a result of incidental findings or screening program (P < 0.001). The groups were similar in terms of clinical characteristics with the only difference being that plaques were more prevalent among ARLC patients (P < 0.001). Differences were observed for median overall survival (OS), ARLC (9 months) and non-ARLC (13 months, P = 0.005), as well for treatment (P = 0.01). After adjusting for age, however, these differences disappeared. Conclusions: Age at diagnosis, pleural plaques, and asymptomatic presentation were the attributes that we identified as significantly different between asbestos-related cancer and other lung cancers. In this cohort, ARLC patients were older diagnosis and with worse overall survival.
Persistent Identifierhttp://hdl.handle.net/10722/326514
ISSN
2023 Impact Factor: 1.4
2023 SCImago Journal Rankings: 0.531
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorHyland, Rebecca A.-
dc.contributor.authorChrzanowska, Agata-
dc.contributor.authorHannaford-Turner, Kirsty-
dc.contributor.authorDavis, Alexander-
dc.contributor.authorKe, Helen-
dc.contributor.authorBradbury, Lauren-
dc.contributor.authorNagrial, Adnan-
dc.contributor.authorMcCaughan, Brian-
dc.contributor.authorHui, Rina-
dc.contributor.authorvan Zandwijk, Nico-
dc.contributor.authorTakahashi, Ken-
dc.contributor.authorKao, Steven C.-
dc.date.accessioned2023-03-10T02:19:49Z-
dc.date.available2023-03-10T02:19:49Z-
dc.date.issued2022-
dc.identifier.citationAsia-Pacific Journal of Clinical Oncology, 2022, v. 18, n. 5, p. e448-e455-
dc.identifier.issn1743-7555-
dc.identifier.urihttp://hdl.handle.net/10722/326514-
dc.description.abstractBackground and objectives: Due to difficulties in identifying sufficient-sized cohorts there remains uncertainty about prognostic and clinical differences that may be unique to asbestos-related lung cancer (ARLC). In this study, we use the Helsinki Criteria to define a group of ex-workers with lung cancer attributable to asbestos exposure and investigate differences that may exist. Methods: A total of 529 patients seeking workers’ compensation for their lung cancer were assigned to either ARLC or the non-ARLC based on parameters defined in the Helsinki Criteria. Clinical and survival details were collected and analyzed. Results: In our study population, ARLC patients were on average older (72.1 ± 7.8) than non-ARLC patients (66.5 ± 10.2, P < 0.001) and were more likely to be diagnosed as a result of incidental findings or screening program (P < 0.001). The groups were similar in terms of clinical characteristics with the only difference being that plaques were more prevalent among ARLC patients (P < 0.001). Differences were observed for median overall survival (OS), ARLC (9 months) and non-ARLC (13 months, P = 0.005), as well for treatment (P = 0.01). After adjusting for age, however, these differences disappeared. Conclusions: Age at diagnosis, pleural plaques, and asymptomatic presentation were the attributes that we identified as significantly different between asbestos-related cancer and other lung cancers. In this cohort, ARLC patients were older diagnosis and with worse overall survival.-
dc.languageeng-
dc.relation.ispartofAsia-Pacific Journal of Clinical Oncology-
dc.subjectasbestos-
dc.subjectcancer risk factors-
dc.subjectcarcinogenesis-
dc.subjectclinical epidemiology-
dc.subjectlung cancer-
dc.titleAsbestos-related lung cancer: Clinical characteristics and survival outcomes in an Australian cohort seeking workers compensation-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/ajco.13664-
dc.identifier.pmid35100476-
dc.identifier.scopuseid_2-s2.0-85123951992-
dc.identifier.volume18-
dc.identifier.issue5-
dc.identifier.spagee448-
dc.identifier.epagee455-
dc.identifier.eissn1743-7563-
dc.identifier.isiWOS:000748698300001-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats